Latest news with #VinitaGupta
Yahoo
27-05-2025
- Business
- Yahoo
Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology
MUMBAI, India, NAPLES, Fla. and CHICAGO, May 27, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) will present data from its Phase 1a clinical trial evaluating LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, from May 30 to June 3, 2025. The presentation titled 'A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors,' will be featured in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session. It can be viewed at Poster Board #422 on June 2, 2025, from 1.30 pm to 4.30 pm (CDT). Key findings from the study include: LNP7457 is generally safe and well tolerated in patients with advanced or metastatic solid tumors, with desirable PK/PD profile and no impact of food on the pharmacokinetics. The maximum tolerated dose, recommended phase 2 dose was determined based on safety, efficacy, PK/PD data, aligning with preclinical findings and the known safety profile of PRMT5 inhibitors. "We are delighted to share the initial results from Phase I study of our PRMT5 Inhibitor, a novel epigenetic onco-therapeutic targeted for monotherapy. We are committed to innovation and advancing cutting-edge science to offer meaningful therapeutic options for patients with difficult-to-treat cancers," said Vinita Gupta, CEO, Lupin. Current data from Lupin indicates that LNP7457 is unique within its field and appears to be safe and well-tolerated as a SAM-competitive PRMT5 inhibitor. Lupin will continue to study the efficacy of LNP7457 in its phase 1b trial in India and explore its potential for treatment of cancers with significant unmet medical needs. Details of the Presentation: Date and time: June 2, 2025, 1:30 pm – 4:30 pm (CDT) Location: Hall A - Posters and Exhibits | McCormick Place, Chicago, IL Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Sub Track: Small Molecules Clinical Trial Registration Number: CTRI/2023/07/054753 Doi: 10.1200/JCO.2025.43.16_suppl.3107 Abstract Number: 3107 Poster Board Number: 422 Abstract link: About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit or follow us on LinkedIn Logo: View original content: SOURCE Lupin Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
26-05-2025
- Business
- Business Upturn
Lupin to present Phase 1 data on LNP7457 cancer drug at ASCO 2025
By News Desk Published on May 26, 2025, 21:24 IST Global pharmaceutical major Lupin Limited will present the Phase 1a clinical trial data of its experimental oncology drug LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 to be held in Chicago, Illinois from May 30 to June 3, 2025. The presentation titled 'A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors' will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session at Poster Board #422 on June 2, 2025, from 1:30 PM to 4:30 PM CDT. Key clinical findings LNP7457 was found to be generally safe and well-tolerated in patients with advanced or metastatic solid tumors. It showed a favorable pharmacokinetic and pharmacodynamic (PK/PD) profile , with no food-related effects on pharmacokinetics. The maximum tolerated dose was identified and will inform the recommended Phase 2 dosage, based on safety, efficacy, and existing preclinical data. Vinita Gupta, CEO of Lupin, commented: 'We are delighted to share the initial results from Phase I study of our PRMT5 Inhibitor, a novel epigenetic onco-therapeutic targeted for monotherapy. We are committed to innovation and advancing cutting-edge science to offer meaningful therapeutic options for patients with difficult-to-treat cancers.' Next steps in development Lupin indicated that LNP7457 is unique within its class as a SAM-competitive PRMT5 inhibitor, and continues to demonstrate promising safety and tolerability. The company plans to advance the molecule into Phase 1b trials in India, aiming to explore its efficacy in treating cancers with significant unmet medical needs. The trial is registered under CTRI/2023/07/054753, and the presentation can be accessed online via the ASCO Abstract link. Disclaimer: This article is for informational purposes only. Business Upturn does not provide any investment advice or drug recommendations. All data regarding clinical trials and pharmaceuticals should be evaluated by medical professionals and regulators. News desk at
Time of India
22-05-2025
- Health
- Time of India
Lupin introduces Honeywell Solstice Air inhalers for sustainable respiratory care
Representative image (Picture credit: X/@LupinGlobal) BENGALURU: Lupin is using Honeywell's Solstice Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions. Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%. ' By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact,' said Vinita Gupta, CEO Lupin. 'Solstice Air can play a critical role in ensuring that Lupin's respiratory inhalers provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions,' said Ashish Modi, President of Honeywell India. 'By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions-reducing practices that support industry advancements. ' Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
New Indian Express
21-05-2025
- Health
- New Indian Express
Sustainable healthcare: Why Lupin-Honeywell partnership is significant
In India, pMDIs—particularly those using HFCs—are a significant source of greenhouse gas emissions due to the high GWP of these propellants. Although dry-powder inhalers (DPIs) are used more frequently, pMDIs contribute far more to emissions. Research shows that a large share of these emissions comes from short-acting beta-2 agonist (SABA) inhalers, especially when asthma is poorly controlled. According to Lupin, its new product is designed for patients with asthma and COPD. Honeywell's Solstice Air offers a low-GWP alternative that could substantially reduce the release of high-impact greenhouse gases, marking a major step forward in reducing the industry's carbon emissions. Technology to reduce harmful greenhouse gas emissions Lupin aims to become the first pharmaceutical company in India to use Honeywell's Solstice Air at scale as a next-generation propellant in pMDIs. Solstice Air provides an alternative to traditional HFC propellants, with the potential to cut greenhouse gas emissions by up to 99.9%. 'Lupin's partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air into our products, we are not only enhancing patient care but also significantly reducing our environmental impact,' claimed Lupin CEO Vinita Gupta in a recent media statement. 'Solstice Air can play a critical role in ensuring that Lupin's respiratory inhalers provide safe and effective treatment options, while also leveraging the latest technology to reduce harmful greenhouse gas emissions,' added Ashish Modi, President, Honeywell India. 'By continuing to research and develop advanced technologies to reduce carbon emissions, Honeywell is committed to driving innovation that enhances healthcare efficacy while pioneering sustainable practices,' Modi claims.
Time of India
20-05-2025
- Business
- Time of India
Lupin partners with Honeywell for usage of propellant for inhalers
Lupin Ltd partners with Honeywell to incorporate 'Solstice Air' propellant in next-generation inhalers for asthma and COPD, aiming to reduce carbon emissions. This collaboration makes Lupin the first Indian pharma company to use Solstice Air at scale in pressurized metered-dose inhalers (pMDIs). Solstice Air offers a sustainable alternative, reducing greenhouse gas emissions by up to 99.9%. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Pharma major Lupin Ltd on Tuesday said it has partnered with Honeywell to use the latter's propellant ' Solstice Air ' to transform respiratory care through the development of next-generation inhalers . Designed for patients with asthma and chronic obstructive pulmonary disease ( COPD ), Honeywell 's 'Solstice Air' has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions, the company said in a statement. Lupin 's partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact ," Lupin CEO Vinita Gupta Energy and Sustainability Solutions Business President Jeff Dormo said,"Solstice Air can play a critical role in ensuring that Lupin life-saving devices provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions ."Lupin said it intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurised metered-dose inhalers (pMDIs).Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9 per cent, it added."By investigating the use of this innovative, nonflammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD," the company terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin, it added.
